Get the latest tech news
Over 60s get long-term protection against RSV from single shot
A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older adults long-term protection against the infection, even if efficacy wanes from season to season. Despite this, just a single dose cut serious illness by nearly two thirds, and…
The massive trial saw 24,972 people aged 60 or older get either the RSVPreF3 OA vaccine (brand name Arexvy, by GSK) or a placebo, administered in 275 clinics across 17 countries across five continents. According to the Centers for Disease Control and Protection (CDC), 100,000 to 150,000 US adults aged 60 and over are hospitalized due to the virus each year and an estimated 6,000 to 10,000 people in this demographic will die from it. After more than 20 years as a writer and editor, the former music journalist went back to university to build on her passion for wildlife and conservation with a Bachelor of Zoology, which unlocked two new loves: sharing animal facts at any opportunity and getting others excited about science.
Or read this on r/tech
